Pfizer (NYSE:PFE) has made significant updates to its diversity, equity, and inclusion (DEI) webpage, becoming the latest Big ...

Pfizer made changes to its DEI webpage, joining other companies across different industries repositioning their messaging ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report). The company’s shares closed ...

Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by ...

Pfizer Inc. appointed the Food and Drug Administration’s former top drug reviewer to serve as its chief medical officer.

A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...

Shares of Pfizer Inc. PFE slid 1.20% to $26.42 Wednesday, on what proved to be an all-around mixed trading session for the ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...